Niall Martin

Niall has over 30 years’ extensive experience in both biotech and pharmaceutical industries, predominately in the DNA Damage Response (DDR) field for cancer therapeutics.  Niall has been the CEO of Artios since setting up the company in 2016 and during this time has raised a total of $320M, with a ground- breaking $153M Series C financing in July 2021.

 

Prior to joining Artios, Niall was a co-founder and Chief Operating Officer at MISSION Therapeutics, a company focused on the commercialisation of expert research into ubiquitin pathways for the treatment of neurological disease, cancers and other diseases. During his time at MISSION, Niall helped establish the deubiquitylating enzyme (DUB) inhibitor platform and helped raise more than $108M in Series A and B financing.

 

Prior to that, Niall was Head of KuDOS Pharmaceuticals in Cambridge, UK (a subsidiary of AstraZeneca) from 2008 to 2010, delivering a number of DDR projects into the AstraZeneca oncology pipeline after it acquisition of KuDOS for $220M.  Niall previously held the role of Director of Drug Discovery, where he established the drug-screening capabilities that underpinned all KuDOS drug discovery programmes. Niall’s most notable achievement was establishing KuDOS’ programme against the DDR target PARP, which resulted in the discovery and development of Lynparza™ (olaparib), the first PARP inhibitor to market.

 

Niall also worked in thrombosis research at Fournier (Dijon, France) and in non-lipid cardiovascular research at Zeneca. He gained his PhD in Zoology from Aberdeen University.